Skip to main content
ANIK logo

ANIK · Anika Therapeutics, Inc. · Documents

Track ANIK — free
$13.62 +0.77 (+5.99%) At close · Nov 18 Play latest call Q3 2026 earnings call transcript
Market Cap
$182.44M
Shares
13.40M
Volume · Nov 18 119.01K Avg daily vol (3M) 107.13K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $112.82M down 5.9% 10-K filed Mar 3, 2026 Quarterly report FY2026 Q3 Revenue $30.59M up 10.0% 10-Q filed Nov 6, 2026 Latest results Revenue rises 10%; 2026 outlook raised, Hyalofast application not approvable 8-K filed Nov 6, 2026 Earnings call Q3 2026 earnings call Held Nov 6, 2026
2026
Nov 6
Earnings call
Revenue rises 10%; 2026 outlook raised, HylaFast PMA not approvable

Anika reported third-quarter revenue of $30.6 million, up 10%, and gross margin of 62%, raising 2026 revenue growth guidance to 6% to 10%. HylaFast’s PMA was deemed not approvable, while Integrity revenue grew more than 30% year over year.

6 source passages
welcome to Anika's third quarter earnings conference call. During the quarter, total revenue was $30.6 million, up 10% from $27.8 million. Gross margin was 62% compared with 56% last year and 65% in the second quarter. We are raising the lower end of the full year 2026 total company revenue growth guidance to 6% to 10%, from 5% to 10% previously, while updating the expected contribution from each channel. In October, we received formal notification from the FDA that our HylaFast PMA is not approvable based primarily on the clinical data included in the submission. Integrity grew more than 30% year-over-year, and it increased sequentially. Open the document at this passage
Nov 6
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue 30,594 thousand USD; net loss 311 thousand

Anika Therapeutics reported revenue of 30,594 thousand U.S. dollars and a net loss of 311 thousand U.S. dollars for the three months ended September 30, 2026.

Revenue $30.59M ▲ 10.0% Net loss $311K Diluted EPS -$0.02
Read from the first part of this long document
4 source passages
Anika Therapeutics, Inc. (the “Company”) is a global leader in the design, development, manufacturing and commercialization of hyaluronic acid (HA) innovations. For the Three Months Ended<br>September 30, | 2026 | 2025 Revenue | 30,594 | 27,817 Net loss | (311) | (2,329) Open the document at this passage
Nov 6
Current report 8-K
Revenue rises 10%; 2026 outlook raised, Hyalofast application not approvable

Anika Therapeutics reported third-quarter revenue of $30.6 million, up 10% year over year, raised 2026 revenue guidance to 6% to 10% and adjusted EBITDA margin guidance to 15% to 17%, while receiving FDA notice that Hyalofast PMA application was not approvable.

Financial results
5 source passages
Anika Therapeutics, Inc. (Nasdaq: ANIK), the global leader in the design, development, manufacturing and commercialization of hyaluronic acid (HA) innovations, today announced financial results for the third quarter of 2026. Total revenue for the third quarter was $30.6 million, compared with $27.8 million in the prior-year period, representing 10% year over year growth. Total Company revenue growth: 6% to 10%, compared to 5% to 10% previously Adjusted EBITDA margin: 15% to 17%, compared to 13% to 17% previously In October, Anika received formal notification from the U.S. Food and Drug Administration (FDA) that its Hyalofast PMA application is not approvable, primarily based on the clinical data included in the submission. Open the document at this passage
Jul 29
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $32.61M ▲ 15.6% Net income $3.31M Diluted EPS $0.24
Apr 30
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $29.61M ▲ 13.2% Net loss $5.06M Diluted EPS -$0.37
Apr 28
Proxy statement DEF 14A Meeting Jun 18, 2026
Proxy statement AI summary on its way
Mar 3
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $112.82M ▼ 5.9% Net loss $10.88M Diluted EPS -$0.76
2025
Mar 17
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $119.91M ▼ 0.7% Net loss $56.39M Diluted EPS -$3.83
2024
Showing 1–50 of 150 documents
Key facts CIK 898437 CUSIP 035255108 13F (30d) 141 filings 126 filers Visit website Investor relations